RAS Pathway Inhibitor (PTEN restoration)
KRAS-mutant cancers (G12D, G12V variants)
PreclinicalActive
Key Facts
Indication
KRAS-mutant cancers (G12D, G12V variants)
Phase
Preclinical
Status
Active
Company
About BCN Biosciences
BCN Biosciences is a preclinical biotech firm targeting high-need oncology segments, specifically KRAS-driven cancers (G12D, G12V) and immune checkpoint regulation via small molecules. The company differentiates itself through a novel mechanism aimed at restoring PTEN expression to combat KRAS mutations and a unique approach to modulating PD-1 in the tumor microenvironment. Founded in 2009, BCN has secured non-dilutive funding through SBIR grants and BARDA contracts, positioning its lead programs for potential partnership and advancement into clinical trials.
View full company profile